Core Viewpoint - The article outlines the "Three Major and One Large" collective decision-making approval system of Jiangsu Lianhuan Pharmaceutical Co., Ltd, aimed at standardizing decision-making behavior, enhancing decision quality, and preventing risks and operational errors [1][2]. Group 1: Major Decision Matters - Major decision matters include significant strategic management issues such as development direction, operational policies, and long-term planning, as well as asset disposal, profit distribution, and high-risk operations [2]. - These decisions must be made by the Party Committee, Shareholders' Meeting, Board of Directors, General Manager's Office, or Workers' Representative Assembly [2]. Group 2: Important Personnel Appointments - Important personnel appointments involve the selection and dismissal of middle and senior management, as well as the delegation or replacement of shareholder representatives in subsidiaries [3]. - It also includes significant rewards and punishments related to management personnel [3]. Group 3: Major Project Arrangements - Major project arrangements refer to projects that significantly impact the company's asset scale, capital structure, resource allocation, and profitability [4]. - Projects with estimated contract values exceeding 4 million RMB for construction, 2 million RMB for major material procurement, and 1 million RMB for service procurement must follow bidding regulations [4]. Group 4: Large Amounts of Fund Operations - Large amounts of fund operations include significant budgeted and non-budgeted fund usage, as well as major donations and sponsorships [4]. - Any fund usage exceeding 3 million RMB must be reported to the Party Committee [4]. Group 5: Decision-Making Procedures - The decision-making process for "Three Major and One Large" matters includes pre-meeting research, collective discussion, and formal voting [7]. - Decisions must be made collectively, and no individual can unilaterally change the collective decision [12]. Group 6: Supervision and Accountability - The company’s Party Secretary, Chairman, and General Manager are the main responsible persons for implementing the decision-making system [18]. - Violations of laws or decision-making rules that result in losses will hold the main responsible person accountable [19]. Group 7: Reporting and Compliance - The implementation of the decision-making system is crucial for preventing corruption and ensuring lawful, scientific, and democratic decision-making [24]. - The company’s disciplinary committee is responsible for monitoring compliance and reporting any violations [26].

General Principles - The purpose of the system is to enhance the governance level of Jiangsu Lianhuan Pharmaceutical Co., Ltd. and to standardize the appointment, performance, and training of the board secretary [1] - The board secretary is a senior management personnel responsible to the company and the board, and must perform duties faithfully and diligently [1] - The board secretary serves as the designated liaison between the company and the Shanghai Stock Exchange, handling information disclosure, corporate governance, and equity management [1] Appointment - The company must appoint a board secretary within three months after the initial public offering or within three months after the previous secretary's departure [2] - Candidates for the board secretary must possess good professional ethics, necessary financial, management, and legal knowledge, relevant work experience, and a qualification certificate recognized by the Shanghai Stock Exchange [2] Disqualification - Individuals with certain disqualifying conditions, such as being banned from the securities market or having received public reprimands from the exchange, cannot serve as board secretaries [2] Dismissal - The company must have sufficient reasons for dismissing a board secretary and cannot dismiss without cause [3] - If a board secretary meets any disqualifying conditions, the company must dismiss them within one month of the occurrence [3] Responsibilities - The board secretary is responsible for managing information disclosure, including external communication, developing disclosure management systems, and ensuring compliance with disclosure obligations [5] - The board secretary assists in strengthening corporate governance mechanisms and managing investor relations [5][6] - The board secretary is also responsible for managing equity matters, including maintaining shareholder records and ensuring compliance with stock trading regulations [5] Training - Candidates for the board secretary position must undergo qualification training and obtain a certificate, with ongoing training required every two years [9] - Training topics include information disclosure, corporate governance, investor relations management, and the rights and obligations of the board secretary [9] Penalties - Serious violations of the management regulations may result in penalties from the Shanghai Stock Exchange, including public reprimands and disqualification from serving as a board secretary [11][12] Legal Responsibilities - The board secretary is subject to legal responsibilities for violations of laws, regulations, and company rules, which may lead to accountability [11]

江苏联环药业股份有限公司 董事、高级管理人员所持本公司股份及其变动管理办法 第一章 总则 第一条 为加强公司董事、高级管理人员（以下简称"高管"）所持本公司 股份及其变动的管理，根据《公司法》《证券法》《上市公司股东减持股份管理 暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》、 《上海证券交易所上市公司自律监管指引第 8 号——股份变动管理》、《上海证 券交易所上市公司自律监管指引第 8 号——股份变动管理》等相关法律、法规及 规范性文件的规定，结合公司实际情况，特制定本办法。 第二条 本办法适用于本公司董事、高管以及本办法第十四条规定的自然人、 法人或其他组织所持本公司股票及其变动的管理。 第三条 公司董事、高管在买卖本公司股票及其衍生品种前，应知悉《公司 法》、《证券法》等法律法规关于内幕交易、操纵市场等禁止行为的规定，不得 进行违法违规交易。 第四条 公司董事、高管所持有的本公司股份，是指登记在其名下和利用他 人账户持有的所有本公司股份。公司董事、高级管理人员从事融资融券交易时， 其所持本公司股份还包括记载在其信用账户内的本公司股份。 第五条 公司董事、高管可以通过上海证券交易所 ...

Core Viewpoint - The document outlines the responsibilities and procedures for independent directors in the annual report preparation and disclosure process to ensure the quality and integrity of information disclosed by the company [1][2][3] Group 1: Responsibilities of Independent Directors - Independent directors must diligently fulfill their responsibilities and obligations during the annual report preparation and disclosure process [1] - They are required to study and implement relevant regulations and guidelines issued by the China Securities Regulatory Commission [1] - Independent directors must receive comprehensive reports on the company's operational status and significant matters from management within 30 days after the end of each fiscal year [1] Group 2: Communication and Meetings - The company must arrange at least one meeting between independent directors and the annual audit CPA after the preliminary audit opinion is issued and before the board meeting to discuss any issues found during the audit [2] - Meeting records must be documented and signed by the involved parties [2] Group 3: Reporting and Opinions - Independent directors are required to provide special explanations and independent opinions on external guarantees and related matters in the annual report [2] - They must sign a written confirmation of the annual report, stating their views on its authenticity, accuracy, and completeness [2] Group 4: Support and Confidentiality - The company must provide necessary conditions for independent directors to effectively exercise their powers, ensuring cooperation from relevant personnel [2][3] - Independent directors have a confidentiality obligation and must not disclose the contents of the annual report before its public release [3] Group 5: Independence and Evaluation - Independent directors must conduct an annual self-assessment of their independence and submit the results to the board [3] - The board is responsible for evaluating the independence of serving independent directors annually and issuing a special opinion to be disclosed alongside the annual report [3]

江苏联环药业股份有限公司 关联交易管理制度 第一章总则 第一条 为规范江苏联环药业股份有限公司（以下简称"公司"或"本公司"） 的关联交易行为，保证关联交易的公允性，维护公司及全体股东的合法权益，根 据《中华人民共和国公司法》、 《中华人民共和国证券法》、 《上市公司信息披露管 理办法》、 《上海证券交易所股票上市规则》 （以下简称"《股票上市规则》"） 《上 第三条 公司的关联人包括关联法人（或者其他组织）和关联自然人。 第四条 具有以下情形之一的法人（或者其他组织），为公司的关联法人 （或者其他组织）： （一）直接或者间接控制公司的法人（或者其他组织）； （二）由前项所述法人（或者其他组织）直接或者间接控制的除公司、控股 子公司及控制的其他主体以外的法人（或者其他组织）； （三）关联自然人直接或者间接控制的、或者担任董事（不含同为双方的独 立董事）、高级管理人员的，除公司、控股子公司及控制的其他主体以外的法人 （或者其他组织）； （四）持有公司 5%以上股份的法人（或者其他组织）及其一致行动人。 第五条 具有以下情形之一的自然人，为公司关联自然人： （一）直接或者间接持有公司 5%以上股份的自然人； 海证 ...

Core Viewpoint - The company has established a management system to prevent the controlling shareholder, actual controller, and related parties from occupying company funds, ensuring the protection of the company's and shareholders' legitimate rights and interests [1][2]. Summary by Sections General Principles - The system aims to strengthen and standardize the company's fund management and prevent fund occupation by controlling shareholders and related parties [1]. - The system applies to fund management between the controlling shareholder, actual controller, and related parties, including subsidiaries within the consolidated financial statements [1]. Definitions of Fund Occupation - Fund occupation includes both operational and non-operational fund occupation [1]. - Operational fund occupation arises from related transactions in production and operation, while non-operational fund occupation includes payments for wages, benefits, and other expenses on behalf of the controlling shareholder or related parties [2]. Principles for Preventing Fund Occupation - The company must strictly prevent fund occupation during operational transactions and cannot provide funds to controlling shareholders or related parties through various means such as prepayments or cost-sharing [3]. - Any related transactions must comply with the Shanghai Stock Exchange's regulations [3]. Measures and Specific Regulations - The company must establish a long-term mechanism to prevent non-operational fund occupation by major shareholders and related parties [4]. - The chairman of the company is the primary responsible person for preventing fund occupation, while the financial department is tasked with implementing preventive measures [4]. Rectification of Fund Occupation - The company must conduct self-inspections regarding fund transactions with controlling shareholders and related parties and rectify any violations promptly [5]. - Funds occupied by controlling shareholders should ideally be repaid in cash, with strict controls on non-cash asset repayments [5][6]. Accountability and Legal Measures - If the controlling shareholder or related parties violate the regulations and cause losses, they must bear compensation responsibilities [6]. - The board of directors can propose the dismissal of responsible directors and senior management if they facilitate or condone fund occupation [6].

General Provisions - The purpose of the insider information management system is to regulate the management of insider information, ensure confidentiality, prevent insider trading, and protect investors' rights [1][2] - Insider information is defined as information that has not been publicly disclosed and could significantly impact the company's operations, finances, or securities trading prices [2][3] Insider Information Confidentiality Management - Insider information personnel have a confidentiality obligation and must not disclose insider information or trade based on it before it is publicly disclosed [4][5] - The company must control the number of individuals who are aware of insider information to a minimum and designate responsible persons for handling significant information [5][6] Registration and Filing Management of Insider Information Personnel - The company is required to maintain a record of insider information personnel, including details such as their names, identification numbers, and the time and manner in which they became aware of the insider information [10][11] - The board of directors is responsible for ensuring the accuracy and completeness of the insider information personnel records, with the chairman being the primary responsible person [5][12] Responsibilities and Penalties - Violations of the insider information management system, such as unauthorized disclosure or insider trading, will result in penalties, which may include warnings, demotions, or termination [12][13] - The company must conduct self-inspections regarding insider trading activities and report findings to regulatory authorities within two working days [12][13]

江苏联环药业股份有限公司 投资者关系管理制度 第一条 为了加强公司与投资者和潜在投资者（以下统称"投资者"）之间的 信息沟通，增进投资者对公司的了解和认同，保护投资者的合法权益，实现公司 价值最大化和股东利益最大化，根据《中华人民共和国公司法》、 《中华人民共和 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》、 引》、 《江苏联环 药业股份有限公司章程》及其它有关法律、法规和规定，结合本公司实际情况， 制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 上市公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的基本原则： （1）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内 部规章制度，以及行业普遍遵守的道德规范和行为准则。 （2）平等性原则。公司开展投资者关系管理活动，应当平等对待所有投资 者，尤其为中小投资者参与活动创造机会、提 ...

江苏联环药业股份有限公司 信息披露事务管理制度 第一章 总则 第一条 为加强江苏联环药业股份有限公司（以下简称"公司"）信息披露事 务管理，确保信息披露的真实、准确、完整、及时，保护投资者的合法权益，根 据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司信息披露管理办法》、《上海证券交易所股 票上市规则》 （以下简称"《股票上市规则》"）、 《上海证券交易所上市公司自律监 管指引第 2 号——信息披露事务管理》等相关法律、行政法规及《江苏联环药业 股份有限公司章程》 （以下简称"公司章程"）的规定，结合本公司实际，制定本 制度。 第二条 本制度所称"信息"，是指对公司股票及其衍生品种交易价格已经或 可能产生较大影响或影响投资者决策的信息，以及其他相关法律、行政法规、部 门规章和证券监管部门要求披露的其他信息。本制度所称"披露"，是指在规定 的时间内、在规定的媒体上、按规定的程序、以规定的披露方式向社会公众公布， 并送达证券监管部门。本制度所称"信息披露义务人"，是指公司及其董事、高 级管理人员、股东、实际控制人，收购人，重大资产重组、再融 ...

Core Points - The article outlines the establishment and operational guidelines of the Compensation and Assessment Committee of Jiangsu Lianhuan Pharmaceutical Co., Ltd, aimed at improving the governance structure and management of compensation for directors and senior management [1][2] Group 1: General Provisions - The Compensation and Assessment Committee is a specialized body established by the board of directors to formulate assessment standards and compensation policies for directors and senior management [1] - The committee consists of three to five members, with a majority being independent directors [2] Group 2: Responsibilities and Authority - The committee is responsible for creating compensation plans based on the roles and responsibilities of directors and senior management, including performance evaluation standards and reward systems [9] - It reviews the performance of directors and senior management and supervises the execution of the company's compensation system [9] Group 3: Decision-Making Procedures - The committee's working group prepares necessary materials for decision-making, including financial indicators and performance evaluations of directors and senior management [5][14] - The committee conducts performance evaluations and proposes compensation amounts and reward methods to the board of directors for approval [14] Group 4: Meeting Rules - The committee meets as needed, with a requirement for two-thirds of members to be present for decisions to be valid [15] - Meetings can be held in person or via other communication methods, and decisions require a majority vote [17] Group 5: Miscellaneous Provisions - The guidelines will be implemented upon approval by the board of directors and will be subject to relevant laws and regulations [25][26] - The board of directors holds the authority to interpret these guidelines [27]